Could Recent Advances in DNA-Loaded Nanoparticles Lead to Effective Inhaled Gene Therapies?
2016; Future Medicine; Volume: 11; Issue: 3 Linguagem: Inglês
10.2217/nnm.15.194
ISSN1748-6963
Autores Tópico(s)RNA Interference and Gene Delivery
ResumoNanomedicineVol. 11, No. 3 EditorialCould recent advances in DNA-loaded nanoparticles lead to effective inhaled gene therapies?Jung Soo SukJung Soo Suk*Author for correspondence: E-mail Address: jsuk@jhmi.edu The Center for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, 400 N. Broadway, Smith Bldg Rm 6029, Baltimore, MD 21231, USAPublished Online:19 Jan 2016https://doi.org/10.2217/nnm.15.194AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: airway mucusanimal modelinhaled gene therapynonviral gene deliveryReferences1 Griesenbach U, Alton EW. Gene transfer to the lung: lessons learned from more than 2 decades of CF gene therapy. Adv. Drug Deliv. Rev. 61(2), 128–139 (2009).Crossref, Medline, CAS, Google Scholar2 Mueller C, Flotte TR. Gene-based therapy for alpha-1 antitrypsin deficiency. COPD 10(Suppl. 1), 44–49 (2013).Crossref, Medline, Google Scholar3 Sinn PL, Burnight ER, Mccray PB Jr. Progress and prospects: prospects of repeated pulmonary administration of viral vectors. Gene Ther. 16(9), 1059–1065 (2009).Crossref, Medline, CAS, Google Scholar4 Padegimas L, Kowalczyk TH, Adams S et al. Optimization of hCFTR lung expression in mice using DNA nanoparticles. Mol. Ther. 20(1), 63–72 (2012).Crossref, Medline, CAS, Google Scholar5 Davies LA, Hyde SC, Nunez-Alonso G et al. The use of CpG-free plasmids to mediate persistent gene expression following repeated aerosol delivery of pDNA/PEI complexes. Biomaterials 33(22), 5618–5627 (2012).Crossref, Medline, CAS, Google Scholar6 Lee YS, Kim SW. Bioreducible polymers for therapeutic gene delivery. J. Control. Release 190, 424–439 (2014).Crossref, Medline, CAS, Google Scholar7 Lin C, Zhong Z, Lok MC et al. Novel bioreducible poly(amido amine)s for highly efficient gene delivery. Bioconjug. Chem. 18(1), 138–145 (2007).Crossref, Medline, CAS, Google Scholar8 Akinc A, Lynn DM, Anderson DG, Langer R. Parallel synthesis and biophysical characterization of a degradable polymer library for gene delivery. J. Am. Chem. Soc. 125(18), 5316–5323 (2003).Crossref, Medline, CAS, Google Scholar9 Aneja MK, Geiger JP, Himmel A, Rudolph C. Targeted gene delivery to the lung. Expert Opin. Drug Deliv. 6(6), 567–583 (2009).Crossref, Medline, CAS, Google Scholar10 Mehta G, Hsiao AY, Ingram M, Luker GD, Takayama S. Opportunities and challenges for use of tumor spheroids as models to test drug delivery and efficacy. J. Control. Release 164(2), 192–204 (2012).Crossref, Medline, CAS, Google Scholar11 Button B, Cai LH, Ehre C et al. A periciliary brush promotes the lung health by separating the mucus layer from airway epithelia. Science 337(6097), 937–941 (2012).Crossref, Medline, CAS, Google Scholar12 Mastorakos P, Da Silva AL, Chisholm J et al. Highly compacted biodegradable DNA nanoparticles capable of overcoming the mucus barrier for inhaled lung gene therapy. Proc. Natl Acad. Sci. USA 112(28), 8720–8725 (2015).Crossref, Medline, CAS, Google Scholar13 Sanders NN, De Smedt SC, Demeester J. Mobility and stability of gene complexes in biogels. J. Control. Release 87(1–3), 117–129 (2003).Crossref, Medline, CAS, Google Scholar14 Sanders N, Rudolph C, Braeckmans K, De Smedt SC, Demeester J. Extracellular barriers in respiratory gene therapy. Adv. Drug Deliv. Rev. 61(2), 115–127 (2009).Crossref, Medline, CAS, Google Scholar15 Lai SK, Wang YY, Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv. Drug Deliv. Rev. 61(2), 158–171 (2009).Crossref, Medline, CAS, Google Scholar16 Di Gioia S, Trapani A, Castellani S et al. Nanocomplexes for gene therapy of respiratory diseases: targeting and overcoming the mucus barrier. Pulm. Pharmacol. Ther. 34, 8–24 (2015).Crossref, Medline, CAS, Google Scholar17 Cone RA. Barrier properties of mucus. Adv. Drug Deliv. Rev. 61(2), 75–85 (2009).Crossref, Medline, CAS, Google Scholar18 Ensign LM, Schneider C, Suk JS, Cone R, Hanes J. Mucus penetrating nanoparticles: biophysical tool and method of drug and gene delivery. Adv. Mater. 24(28), 3887–3894 (2012).Crossref, Medline, CAS, Google Scholar19 Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv. Drug Deliv. Rev. doi:10.1016/j.addr.2015.09.012 (2015) (Epub ahead of print).Google Scholar20 Henderson AG, Ehre C, Button B et al. Cystic fibrosis airway secretions exhibit mucin hyperconcentration and increased osmotic pressure. J. Clin. Invest. 124(7), 3047–3060 (2014).Crossref, Medline, CAS, Google Scholar21 Anderson WH, Coakley RD, Button B et al. The relationship of mucus concentration (hydration) to mucus osmotic pressure and transport in chronic bronchitis. Am. J. Respir. Crit. Care Med. 192(2), 182–190 (2015).Crossref, Medline, Google Scholar22 Suk JS, Lai SK, Wang YY et al. The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles. Biomaterials 30(13), 2591–2597 (2009).Crossref, Medline, CAS, Google Scholar23 Yuan S, Hollinger M, Lachowicz-Scroggins ME et al. Oxidation increases mucin polymer cross-links to stiffen airway mucus gels. Sci. Transl. Med. 7(276), 276ra227 (2015).Crossref, Google Scholar24 Alpar HO, Somavarapu S, Atuah KN, Bramwell VW. Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. Adv. Drug Deliv. Rev. 57(3), 411–430 (2005).Crossref, Medline, CAS, Google Scholar25 Forier K, Messiaen AS, Raemdonck K et al. Transport of nanoparticles in cystic fibrosis sputum and bacterial biofilms by single-particle tracking microscopy. Nanomedicine (Lond.) 8(6), 935–949 (2013).Link, CAS, Google Scholar26 Suk JS, Kim AJ, Trehan K et al. Lung gene therapy with highly compacted DNA nanoparticles that overcome the mucus barrier. J. Control. Release 178C, 8–17 (2014).Crossref, Google Scholar27 Braeckmans K, Peeters L, Sanders NN, De Smedt SC, Demeester J. Three-dimensional fluorescence recovery after photobleaching with the confocal scanning laser microscope. Biophys. J. 85(4), 2240–2252 (2003).Crossref, Medline, CAS, Google Scholar28 Hida K, Lai SK, Suk JS, Won SY, Boyle MP, Hanes J. Common gene therapy viral vectors do not efficiently penetrate sputum from cystic fibrosis patients. PLoS ONE 6(5), e19919 (2011).Crossref, Medline, CAS, Google Scholar29 Schuster BS, Kim AJ, Kays JC et al. Overcoming the cystic fibrosis sputum barrier to leading adeno-associated virus gene therapy vectors. Mol. Ther. 22(8), 1484–1493 (2014).Crossref, Medline, CAS, Google Scholar30 Schuster BS, Suk JS, Woodworth GF, Hanes J. Nanoparticle diffusion in respiratory mucus from humans without lung disease. Biomaterials 34(13), 3439–3446 (2013).Crossref, Medline, CAS, Google Scholar31 Suk JS, Lai SK, Boylan NJ, Dawson MR, Boyle MP, Hanes J. Rapid transport of muco-inert nanoparticles in cystic fibrosis sputum treated with N-acetyl cysteine. Nanomedicine (Lond.) 6(2), 365–375 (2011).Link, CAS, Google Scholar32 Suk JS, Boylan NJ, Trehan K et al. N-acetylcysteine enhances cystic fibrosis sputum penetration and airway gene transfer by highly compacted DNA nanoparticles. Mol. Ther. 19(11), 1981–1989 (2011).Crossref, Medline, CAS, Google Scholar33 Guilbault C, Saeed Z, Downey GP, Radzioch D. Cystic fibrosis mouse models. Am. J. Respir. Cell Mol. Biol. 36(1), 1–7 (2007).Crossref, Medline, CAS, Google Scholar34 Hoegger MJ, Fischer AJ, Mcmenimen JD et al. Impaired mucus detachment disrupts mucociliary transport in a piglet model of cystic fibrosis. Science 345(6198), 818–822 (2014).Crossref, Medline, CAS, Google Scholar35 Mall M, Grubb BR, Harkema JR, O'Neal WK, Boucher RC. Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice. Nat. Med. 10(5), 487–493 (2004).Crossref, Medline, CAS, Google Scholar36 Yan Z, Stewart ZA, Sinn PL et al. Ferret and pig models of cystic fibrosis: prospects and promise for gene therapy. Hum. Gene Ther. Clin. Dev. 26(1), 38–49 (2015).Crossref, Medline, CAS, Google Scholar37 Alton EW, Armstrong DK, Ashby D et al. Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, Phase 2b trial. Lancet Respir. Med. doi:10.1016/S2213-2600(15)00245-3 (2015) (Epub ahead of print).Crossref, Medline, Google Scholar38 Griesenbach U, Alton EW. Progress in gene and cell therapy for cystic fibrosis lung disease. Curr. Pharm. Des. 18(5), 642–662 (2012).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByPLGA-Based Micro/Nanoparticles: An Overview of Their Applications in Respiratory Diseases22 February 2023 | International Journal of Molecular Sciences, Vol. 24, No. 5Recent Advances in Nanomaterials for Asthma Treatment20 November 2022 | International Journal of Molecular Sciences, Vol. 23, No. 22Cell and Gene Therapies for Chronic Inflammatory Lung Diseases: Emerging Technological Trends and Advancements in Respiratory Medicine24 March 2022Enhancing nanoparticle penetration through airway mucus to improve drug delivery efficacy in the lung7 December 2020 | Expert Opinion on Drug Delivery, Vol. 18, No. 5An Adeno-Associated Viral Vector Capable of Penetrating the Mucus Barrier to Inhaled Gene TherapyMolecular Therapy - Methods & Clinical Development, Vol. 9Generation of Well-Defined Micro/Nanoparticles via Advanced Manufacturing Techniques for Therapeutic Delivery18 April 2018 | Materials, Vol. 11, No. 4Barriers to inhaled gene therapy of obstructive lung diseases: A reviewJournal of Controlled Release, Vol. 240 Vol. 11, No. 3 Follow us on social media for the latest updates Metrics Downloaded 107 times History Published online 19 January 2016 Published in print February 2016 Information© Future Medicine LtdKeywordsairway mucusanimal modelinhaled gene therapynonviral gene deliveryFinancial & competing interests disclosureThe author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patent received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download
Referência(s)